Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 + Cetrelimab vs Cetrelimab in Muscle-Invasive Bladder Cancer
NCT04919512Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of gemcitabine-releasing intravesical system in muscle-invasive bladder cancer (MIBC) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Pathologic Complete Response Rate at Week 12. Started Jul 2022; status: completed.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04919512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919512.